
Isomorphic Labs Raises $5B Series C to Push AI Drug Candidates to Clinical Trials
By Ali Al-Montaser — Senior AI Technical Editor
Isomorphic Labs, the DeepMind spinout, closed a $5 billion Series C led by Greenoaks and Sequoia Capital to advance its AI-designed drug candidates into clinical trials after positive preclinical results in oncology and immunology. The round follows a $2.1 billion Series B in May, bringing total disclosed funding to over $7.1 billion in one year, amid reports of a targeted $50 billion valuation. The company's engine builds on AlphaFold protein-structure prediction and is backed by partnerships with Eli Lilly, Novartis, and Johnson & Johnson.
Executive Overview
Isomorphic Labs, the drug-discovery spinout from Google DeepMind, announced on November 17, 2026, the close of a $5 billion Series C funding round led by Greenoaks and Sequoia Capital. The capital will accelerate its AI-designed drug candidates into clinical trials following positive preclinical results in oncology and immunology. The round follows a $2.1 billion Series B in May and brings total disclosed funding to over $7.1 billion in a single year, amid Bloomberg reports of a targeted $50 billion valuation. The company's engine is built on AlphaFold protein-structure prediction and supported by partnerships with Eli Lilly, Novartis, and Johnson & Johnson.
📊 Official Technical Specifications & Data Sheet
| Technical Axis | Confirmed Official Data |
|---|---|
| 💰 Pricing & Usage Cost | No token pricing or subscription plans; Isomorphic Labs is an enterprise drug-discovery platform, not a public API. Funding: $5 billion (Series C), $2.1 billion (Series B in May), reported $50 billion valuation (Bloomberg). |
| 🌐 Platforms & Immediate Availability | Internal platform for Isomorphic Labs; no public availability or API. Enterprise partnerships with Eli Lilly, Novartis, and Johnson & Johnson. |
| ⚡ Performance & Speed Metrics | Positive preclinical results in oncology and immunology (no specific numerical percentages disclosed). Drug-design engine relies on multiple simulation models in chemistry. |
| 🛡️ Security & Breach Resistance | Not mentioned in the announcement; closed enterprise environment with major pharmaceutical partners. |
| 🧠 Context Window | Not applicable; the system is not a general-purpose language model but a molecule and drug design engine. |
| 🌍 Arabic Language & Regional Support | Not applicable to a public interface; no Arabic version or announced regional coverage. |
Deep-Dive Features & Architecture
Isomorphic Labs' drug-design engine uses a suite of AI simulation models to explore multiple chemical spaces, fundamentally built on the AlphaFold model for predicting three-dimensional protein structures from genetic sequences. The company announced that its program achieved positive preclinical results in oncology and immunology, paving the way for clinical trials. This new round—the first since founder and CEO Demis Hassabis stepped down as head of DeepMind to focus on drug discovery—will be directed toward engine development and expansion into new drug modalities.
The round included new and existing investors: it was led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining as a new investor, alongside all existing investors including GV and Capital G (Alphabet's investment arms), Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund. The round follows the $2.1 billion Series B in May, bringing total announced funding to over $7.1 billion in one year. The company did not disclose its new valuation, but Bloomberg reports indicated it sought funding at a $50 billion valuation.
Benchmark & Competitive Performance
No standard performance benchmarks have been published for the Isomorphic Labs engine, but the funding context is comparable: the $5 billion Series C far exceeds the $2.1 billion Series B and places the company among the highest-valued startups in AI biotech (reported $50 billion valuation). For comparison, India's Bharat Semi raised $24 million in a seed round, and Science Corporation reached a $3.5 billion valuation after new funding, highlighting the exceptional scale of Isomorphic Labs' funding in the AI-powered drug sector.
Industry Impact & Enterprise Adoption
Isomorphic Labs does not offer a public API or token pricing, so there is no direct impact on Arabic development costs or token efficiency. However, the massive funding reinforces AlphaFold's position as an open-source engine for protein-structure prediction, which benefits Arab researchers in universities and biomedical research centers through open tools based on AlphaFold. Partnerships with major pharmaceutical companies may later open opportunities for regional collaboration in clinical trials, but there is currently no announced plan to support the Arabic language or expand in the region.
Conclusion
The $5 billion Series C represents a strong vote of confidence in the AI-driven drug discovery model and positions Isomorphic Labs to transition from preclinical promise to clinical reality. With backing from top-tier investors and strategic partnerships with Big Pharma, the company is scaling its AlphaFold-based engine to tackle new drug modalities. While no public product or pricing exists, the funding signals a maturing ecosystem where AI is becoming central to pharmaceutical R&D—a development worth watching for researchers and enterprises globally.
Media Source: TechCrunch AI | Fact Verification & Analysis: AI Tools Oasis
Frequently Asked Questions
Isomorphic Labs raised $5 billion in a Series C funding round led by Greenoaks and Sequoia Capital, with participation from Andreessen Horowitz and existing investors.
The company has not officially disclosed its new valuation, but Bloomberg reported in November 2026 that it was seeking to raise funding at a $50 billion valuation.
The funding will be used to further develop its AI-powered drug design engine, expand into new drug modalities, and advance drug candidates toward clinical trials following positive preclinical results in oncology and immunology.
The round was led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining as a new investor, alongside existing investors including GV, Capital G, Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund.
Isomorphic Labs spun out of Google DeepMind in 2021, and its engine relies on the AlphaFold model for predicting three-dimensional protein structures. Its founder, Demis Hassabis, and John Jumper won the Nobel Prize in Chemistry for their work on AlphaFold.

AI Tools Oasis Team
Bringing you the latest news and analysis in the world of Artificial Intelligence with accuracy and credibility. Follow us for all updates.


